KRAS and neoplasm: These achieve even higher tumor responses in metastatic colon cancers when administered with an oxaliplatin-based chemotherapy for Kras wild-type tumors; however, those with Kras mutations experience poor effectiveness, and mandated preoperative testing was introduced for treatment eligibility [43,44,45,46,47,48,49].